| Symbol | Name | Last Trade Price | Change |
|---|---|---|---|
BMY Daily Activity
| Open | P/E Ratio | 52 week Range | Percent Change From 52 week High |
|---|---|---|---|
BMY Dividend Yield Chart
BMY Dividend Data
| Dividend Yield | Dividend per Share | Ex-Dividend Date | Dividend Pay Date |
|---|---|---|---|
BMY Bristol-Myers Squibb Co. Dividend Yield
BMY Dividend Payout History Graph
| Symbol | Name | Last Trade Price | Change | Change (%) | Earnings per Share |
|---|---|---|---|---|---|
News headlines for BMY
BMY Company Information
| BMY Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York. |
| BMY HQ Address: 345 PARK AVE, NEW YORK, NY 10154 |
| BMY Website URL: http://www.bms.com |
Similar Companies |